PureTech
Developing and commercializing highly differentiated medicines for devastating diseases.
Launch date
Employees
Market cap
€421m
Enterprise valuation
(€19m) (Public information from Sep 2024)
Share price
£1.45109 PRTC.L
Boston Massachusetts (HQ)
Notable known LPs: JDRF
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 8.3m | 10.0m | 2.1m | <1m | 28.4m | 35.2m | 22.8m |
% growth | (4 %) | 20 % | (79 %) | (64 %) | 3691 % | 24 % | (35 %) |
EBITDA | (145m) | (215m) | (203m) | (132m) | (130m) | (137m) | (140m) |
% EBITDA margin | (1735 %) | (2153 %) | (9699 %) | (17641 %) | (457 %) | (389 %) | (613 %) |
Profit | 6.0m | (60.6m) | (50.4m) | (65.7m) | (128m) | (115m) | (147m) |
% profit margin | 72 % | (607 %) | (2409 %) | (8760 %) | (449 %) | (328 %) | (647 %) |
EV / revenue | 147.7x | 72.6x | 267.9x | 607.3x | 3.7x | 2.0x | 2.9x |
EV / EBITDA | -8.5x | -3.4x | -2.8x | -3.4x | -0.8x | -0.5x | -0.5x |
R&D budget | 61.2m | 81.5m | 116m | 73.7m | - | - | - |
R&D % of revenue | 734 % | 817 % | 5556 % | 9831 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
N/A | $50.0m | Late VC | |
N/A | N/A | IPO | |
* | $11.4m | Grant | |
Total Funding | €55.8m |
Recent News about PureTech
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
By Country
By Industry
Investments by PureTech
EditACQUISITION by Bristol-Myers Squibb Dec 2023
exited
ACQUISITION by PureTech Jun 2021